Vivimed Labs is locked at upper circuit limit of Rs. 12.84, up by 0.61 points or 4.99% from its previous closing of Rs. 12.23 on the BSE.
The scrip opened at Rs. 12.84 and has touched a high and low of Rs. 12.84 and Rs. 12.84 respectively. So far shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 19.00 on 23-Sep-2019 and a 52 week low of Rs. 6.50 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 12.84 and Rs. 10.06 respectively. The current market cap of the company is Rs. 101.40 crore.
The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.56% and 63.53% respectively.
Vivimed Labs has received export order for supply of ‘Favulous’ tablets 200 mg (Favipiravir). Favulous tablets 200 mg (Favipiravir) is used for the treatment of mild to moderate cases of Covid-19. Favipiravir is the only oral antiviral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid19 disease. The initial Export order value is worth over Rs 100 Million. The company expects to receive further repeat orders during the Year.
The company is launching Favulous at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with company’s continuous efforts to support world’s pandemic response. The company will work closely with the various governments and medical community to ensure availability of Favulous to patients across the world.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
